Search
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalBosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive … Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrileFlupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe.
Categories: Heterocyclic Compounds, 1-RingIMA901
go.drugbank.com/drugs/DB06628InvestigationalIMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis … Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InducersProducts: CRESEMBA ® CAPSULAS, CRESEMBA® 200 MG POLVO LIOFILIZADO ESTERIL PARA RECONSTITUIRQuarfloxin
go.drugbank.com/drugs/DB06638InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBevasiranib
go.drugbank.com/drugs/DB06642InvestigationalBevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).
Categories: Compounds used in a research, industrial, or household settingSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Cytochrome P-450 Substrates, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesGMK
go.drugbank.com/drugs/DB06661ExperimentalGMK vaccine (a ganglioside conjugate vaccine coupled to keyhole limpet hemocyanin and formulated with the adjuvant QS-21) for the potential treatment of melanoma